Benjamin Edwards Inc. Invests $652,000 in DexCom, Inc. (NASDAQ:DXCM)

Benjamin Edwards Inc. purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 9,726 shares of the medical device company's stock, valued at approximately $652,000.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter valued at about $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. Riverview Trust Co raised its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC lifted its holdings in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after purchasing an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the 3rd quarter worth approximately $57,000. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Wells Fargo & Company raised their price target on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Finally, Piper Sandler reissued an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $104.59.

DexCom Price Performance

NASDAQ:DXCM traded down $1.20 during mid-day trading on Friday, reaching $77.72. 2,644,207 shares of the company were exchanged, compared to its average volume of 3,793,395. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a market cap of $30.36 billion, a PE ratio of 46.54, a PEG ratio of 2.48 and a beta of 1.12. The company has a fifty day moving average of $72.55 and a 200 day moving average of $85.74.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.